 Jeffrey Goldstein
Concepts (731)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Fusion | 15 | 2022 | 17 | 2.120 |
Why?
| | Lumbar Vertebrae | 14 | 2019 | 26 | 2.030 |
Why?
| | Middle Aged | 55 | 2019 | 613 | 1.940 |
Why?
| | Humans | 115 | 2023 | 6579 | 1.940 |
Why?
| | Male | 76 | 2023 | 3113 | 1.600 |
Why?
| | Spinal Diseases | 7 | 2020 | 9 | 1.570 |
Why?
| | Aged | 43 | 2022 | 393 | 1.480 |
Why?
| | Cytochrome P-450 Enzyme System | 16 | 2001 | 106 | 1.460 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 13 | 2009 | 54 | 1.400 |
Why?
| | Female | 70 | 2023 | 3362 | 1.390 |
Why?
| | Intervertebral Disc | 6 | 2011 | 6 | 1.240 |
Why?
| | Prostatic Neoplasms | 5 | 2017 | 23 | 1.170 |
Why?
| | Adult | 42 | 2021 | 1139 | 1.160 |
Why?
| | Arthroplasty, Replacement | 5 | 2011 | 7 | 1.140 |
Why?
| | Mixed Function Oxygenases | 11 | 2009 | 25 | 1.130 |
Why?
| | Treatment Outcome | 27 | 2020 | 633 | 1.080 |
Why?
| | Cardiac Catheterization | 6 | 2017 | 24 | 1.060 |
Why?
| | Angioplasty, Balloon | 6 | 2017 | 7 | 1.010 |
Why?
| | Atrial Fibrillation | 4 | 2020 | 5 | 1.000 |
Why?
| | Aortic Aneurysm, Thoracic | 3 | 2017 | 4 | 0.990 |
Why?
| | Myocardial Infarction | 11 | 2005 | 16 | 0.970 |
Why?
| | Postoperative Complications | 16 | 2022 | 194 | 0.940 |
Why?
| | Retrospective Studies | 22 | 2023 | 1278 | 0.930 |
Why?
| | Spine | 4 | 2019 | 7 | 0.850 |
Why?
| | Blood Vessel Prosthesis Implantation | 4 | 2017 | 5 | 0.840 |
Why?
| | Foreign-Body Migration | 2 | 2020 | 4 | 0.800 |
Why?
| | Device Removal | 2 | 2020 | 15 | 0.790 |
Why?
| | Stents | 12 | 2017 | 15 | 0.790 |
Why?
| | Ventricular Function, Right | 8 | 1998 | 17 | 0.780 |
Why?
| | Bone Screws | 5 | 2011 | 5 | 0.770 |
Why?
| | Coronary Vessels | 6 | 2004 | 9 | 0.770 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 3 | 0.740 |
Why?
| | Robotic Surgical Procedures | 1 | 2020 | 2 | 0.730 |
Why?
| | Animals | 29 | 2017 | 674 | 0.700 |
Why?
| | Mephenytoin | 6 | 1999 | 6 | 0.690 |
Why?
| | Cervical Vertebrae | 4 | 2010 | 7 | 0.680 |
Why?
| | Range of Motion, Articular | 6 | 2011 | 13 | 0.660 |
Why?
| | Aged, 80 and over | 18 | 2020 | 165 | 0.660 |
Why?
| | Angioplasty, Balloon, Coronary | 7 | 2003 | 7 | 0.630 |
Why?
| | Intervertebral Disc Displacement | 4 | 2010 | 4 | 0.620 |
Why?
| | Coronary Angiography | 7 | 2003 | 9 | 0.620 |
Why?
| | Bone Transplantation | 6 | 2011 | 9 | 0.610 |
Why?
| | Warfarin | 4 | 2009 | 16 | 0.610 |
Why?
| | Polymorphism, Genetic | 11 | 2009 | 100 | 0.610 |
Why?
| | Aorta, Abdominal | 1 | 2017 | 1 | 0.610 |
Why?
| | Embolism | 1 | 2017 | 1 | 0.610 |
Why?
| | Vena Cava, Inferior | 1 | 2017 | 4 | 0.610 |
Why?
| | Surgical Instruments | 1 | 2017 | 6 | 0.610 |
Why?
| | Breast Neoplasms | 2 | 2016 | 40 | 0.600 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 34 | 0.600 |
Why?
| | Bone Neoplasms | 1 | 2017 | 24 | 0.600 |
Why?
| | Catheterization, Central Venous | 1 | 2017 | 19 | 0.600 |
Why?
| | Pregnancy Complications | 1 | 2017 | 8 | 0.600 |
Why?
| | Stress, Physiological | 1 | 2017 | 7 | 0.590 |
Why?
| | Metabolic Diseases | 1 | 2017 | 12 | 0.590 |
Why?
| | Decompression, Surgical | 2 | 2015 | 5 | 0.570 |
Why?
| | Prostheses and Implants | 8 | 2011 | 16 | 0.550 |
Why?
| | Prosthesis Implantation | 3 | 2010 | 8 | 0.550 |
Why?
| | Workers' Compensation | 1 | 2015 | 1 | 0.540 |
Why?
| | Prospective Studies | 15 | 2023 | 520 | 0.540 |
Why?
| | Diskectomy | 3 | 2010 | 3 | 0.540 |
Why?
| | Follow-Up Studies | 21 | 2020 | 326 | 0.540 |
Why?
| | Myocardial Ischemia | 5 | 1995 | 5 | 0.530 |
Why?
| | Cleft Palate | 3 | 2023 | 13 | 0.520 |
Why?
| | Prosthesis Design | 7 | 2017 | 14 | 0.510 |
Why?
| | Cancer Care Facilities | 1 | 2014 | 1 | 0.510 |
Why?
| | Low Back Pain | 4 | 2011 | 5 | 0.500 |
Why?
| | Anticoagulants | 3 | 2009 | 20 | 0.500 |
Why?
| | Biomedical Research | 1 | 2014 | 20 | 0.490 |
Why?
| | Algorithms | 2 | 2017 | 104 | 0.490 |
Why?
| | Hemodynamics | 7 | 1995 | 15 | 0.470 |
Why?
| | Coronary Disease | 5 | 2000 | 10 | 0.470 |
Why?
| | Atrial Appendage | 3 | 2020 | 3 | 0.470 |
Why?
| | Prostate-Specific Antigen | 3 | 2017 | 7 | 0.460 |
Why?
| | Bone Plates | 6 | 2004 | 6 | 0.450 |
Why?
| | United States | 15 | 2017 | 640 | 0.440 |
Why?
| | Femur | 2 | 2011 | 12 | 0.410 |
Why?
| | Time Factors | 15 | 2020 | 254 | 0.410 |
Why?
| | Pregnancy | 8 | 2023 | 188 | 0.400 |
Why?
| | Radiography | 9 | 2012 | 49 | 0.400 |
Why?
| | Cardiac Surgical Procedures | 4 | 2020 | 33 | 0.390 |
Why?
| | Phenotype | 9 | 2023 | 244 | 0.380 |
Why?
| | Spondylosis | 1 | 2010 | 1 | 0.370 |
Why?
| | Risk Factors | 12 | 2023 | 471 | 0.370 |
Why?
| | Ciliary Motility Disorders | 1 | 2010 | 1 | 0.370 |
Why?
| | HIV Infections | 2 | 2023 | 51 | 0.360 |
Why?
| | Graft Occlusion, Vascular | 5 | 2003 | 5 | 0.360 |
Why?
| | Recovery of Function | 7 | 2011 | 22 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2023 | 342 | 0.340 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2008 | 16 | 0.330 |
Why?
| | Anticonvulsants | 2 | 1999 | 27 | 0.330 |
Why?
| | Prosthesis Failure | 1 | 2008 | 3 | 0.320 |
Why?
| | Popliteal Artery | 3 | 2013 | 3 | 0.320 |
Why?
| | Femoral Artery | 3 | 2013 | 4 | 0.320 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 29 | 0.310 |
Why?
| | Patient Satisfaction | 5 | 2019 | 40 | 0.310 |
Why?
| | Echocardiography | 13 | 1995 | 92 | 0.310 |
Why?
| | Placenta | 3 | 2023 | 23 | 0.310 |
Why?
| | Aortography | 2 | 2017 | 4 | 0.310 |
Why?
| | Drinking | 2 | 2003 | 8 | 0.300 |
Why?
| | Heart Septal Defects, Ventricular | 2 | 2005 | 6 | 0.300 |
Why?
| | Vagina | 3 | 2017 | 10 | 0.280 |
Why?
| | Electrocardiography | 6 | 1998 | 19 | 0.280 |
Why?
| | Dogs | 10 | 1998 | 26 | 0.270 |
Why?
| | Absorbable Implants | 3 | 2004 | 3 | 0.260 |
Why?
| | Craniosynostoses | 3 | 2004 | 4 | 0.260 |
Why?
| | Tomography, X-Ray Computed | 7 | 2017 | 123 | 0.260 |
Why?
| | Fetal Growth Retardation | 2 | 2023 | 4 | 0.260 |
Why?
| | Steroid Hydroxylases | 3 | 1998 | 12 | 0.260 |
Why?
| | Bufonidae | 2 | 2004 | 2 | 0.250 |
Why?
| | Vasoconstriction | 1 | 2004 | 3 | 0.250 |
Why?
| | Pyrrolidines | 1 | 2004 | 2 | 0.250 |
Why?
| | Indoles | 1 | 2004 | 4 | 0.250 |
Why?
| | Infant | 11 | 2023 | 1394 | 0.250 |
Why?
| | Intraoperative Complications | 2 | 2009 | 6 | 0.250 |
Why?
| | Disability Evaluation | 6 | 2011 | 14 | 0.250 |
Why?
| | Alloys | 3 | 2013 | 3 | 0.240 |
Why?
| | Surgical Flaps | 2 | 1994 | 9 | 0.240 |
Why?
| | Angiotensin II | 1 | 2003 | 1 | 0.240 |
Why?
| | Skin Physiological Phenomena | 1 | 2003 | 1 | 0.240 |
Why?
| | Dehydration | 1 | 2003 | 3 | 0.240 |
Why?
| | Micrognathism | 1 | 2023 | 2 | 0.240 |
Why?
| | Airway Obstruction | 1 | 2023 | 14 | 0.240 |
Why?
| | Spondylolisthesis | 2 | 2015 | 2 | 0.240 |
Why?
| | Heart Ventricles | 6 | 1998 | 55 | 0.230 |
Why?
| | Hospital Costs | 2 | 2007 | 29 | 0.230 |
Why?
| | Language Development | 2 | 2008 | 7 | 0.230 |
Why?
| | HIV | 1 | 2023 | 5 | 0.230 |
Why?
| | Arterial Occlusive Diseases | 3 | 2012 | 4 | 0.230 |
Why?
| | Peroxidase | 2 | 1993 | 3 | 0.230 |
Why?
| | Tyrosine | 2 | 1993 | 4 | 0.230 |
Why?
| | Embolization, Therapeutic | 1 | 2003 | 13 | 0.230 |
Why?
| | Neutrophils | 2 | 1993 | 13 | 0.230 |
Why?
| | Coronary Aneurysm | 1 | 2003 | 1 | 0.230 |
Why?
| | Abruptio Placentae | 1 | 2023 | 1 | 0.230 |
Why?
| | Brachytherapy | 3 | 2017 | 3 | 0.230 |
Why?
| | Aorta | 1 | 2003 | 9 | 0.230 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 182 | 0.220 |
Why?
| | Surgical Wound Infection | 3 | 2015 | 46 | 0.220 |
Why?
| | Infant, Newborn | 7 | 2023 | 785 | 0.220 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 45 | 0.220 |
Why?
| | Alleles | 6 | 2001 | 206 | 0.210 |
Why?
| | Scheuermann Disease | 1 | 2022 | 1 | 0.210 |
Why?
| | Pedicle Screws | 1 | 2022 | 1 | 0.210 |
Why?
| | Urinary Retention | 1 | 2022 | 6 | 0.210 |
Why?
| | Palatal Obturators | 1 | 2002 | 1 | 0.210 |
Why?
| | Phonetics | 1 | 2002 | 1 | 0.210 |
Why?
| | Myocardial Contraction | 6 | 1995 | 13 | 0.210 |
Why?
| | Child | 13 | 2023 | 3193 | 0.210 |
Why?
| | Atrial Function | 2 | 1993 | 2 | 0.210 |
Why?
| | Chlorpyrifos | 1 | 2001 | 1 | 0.210 |
Why?
| | Systole | 3 | 1995 | 13 | 0.210 |
Why?
| | Respiratory Insufficiency | 1 | 2022 | 13 | 0.210 |
Why?
| | Testosterone | 1 | 2001 | 11 | 0.210 |
Why?
| | Adolescent | 14 | 2019 | 2078 | 0.210 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 80 | 0.210 |
Why?
| | Pain Measurement | 4 | 2011 | 48 | 0.200 |
Why?
| | Fetus | 3 | 2021 | 19 | 0.200 |
Why?
| | Lordosis | 1 | 2001 | 1 | 0.200 |
Why?
| | DiGeorge Syndrome | 1 | 2021 | 7 | 0.200 |
Why?
| | Internal Fixators | 1 | 2001 | 4 | 0.200 |
Why?
| | Rare Diseases | 1 | 2022 | 39 | 0.200 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 1 | 0.200 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 16 | 0.200 |
Why?
| | Pregnancy Trimester, Second | 1 | 2021 | 2 | 0.200 |
Why?
| | Patient Discharge | 1 | 2022 | 57 | 0.200 |
Why?
| | Premature Birth | 2 | 2021 | 7 | 0.200 |
Why?
| | Shock, Septic | 1 | 2021 | 5 | 0.200 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 15 | 0.200 |
Why?
| | Escherichia coli Infections | 1 | 2021 | 18 | 0.200 |
Why?
| | Genomics | 1 | 2022 | 90 | 0.200 |
Why?
| | Gene Frequency | 2 | 2001 | 90 | 0.200 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 37 | 0.190 |
Why?
| | Coronary Thrombosis | 3 | 1995 | 3 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2017 | 208 | 0.190 |
Why?
| | Radiopharmaceuticals | 2 | 2017 | 5 | 0.190 |
Why?
| | Sequence Analysis, DNA | 4 | 2022 | 111 | 0.190 |
Why?
| | Echocardiography, Doppler | 2 | 2020 | 13 | 0.190 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 18 | 0.190 |
Why?
| | Endovascular Procedures | 2 | 2017 | 6 | 0.190 |
Why?
| | Forecasting | 2 | 2020 | 22 | 0.190 |
Why?
| | Prostatectomy | 2 | 2017 | 3 | 0.190 |
Why?
| | Heart Septum | 4 | 1994 | 6 | 0.190 |
Why?
| | Child, Preschool | 11 | 2019 | 1476 | 0.190 |
Why?
| | Septal Occluder Device | 1 | 2020 | 3 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2017 | 5 | 0.190 |
Why?
| | Thromboembolism | 1 | 2020 | 4 | 0.190 |
Why?
| | Foreign-Body Reaction | 3 | 2004 | 6 | 0.190 |
Why?
| | Heart Transplantation | 3 | 1995 | 16 | 0.190 |
Why?
| | Cytochrome P-450 CYP2C19 | 8 | 1999 | 64 | 0.180 |
Why?
| | Rats | 9 | 1997 | 107 | 0.180 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2020 | 1 | 0.180 |
Why?
| | Aortic Valve | 1 | 2020 | 4 | 0.180 |
Why?
| | Aortic Valve Stenosis | 1 | 2020 | 3 | 0.180 |
Why?
| | History, 20th Century | 1 | 2020 | 7 | 0.180 |
Why?
| | History, 21st Century | 1 | 2020 | 7 | 0.180 |
Why?
| | Data Mining | 1 | 2019 | 6 | 0.180 |
Why?
| | Stroke Volume | 1 | 2020 | 19 | 0.180 |
Why?
| | Silicon Dioxide | 2 | 1997 | 2 | 0.180 |
Why?
| | Silicone Oils | 2 | 1997 | 2 | 0.180 |
Why?
| | Surgeons | 1 | 2019 | 6 | 0.180 |
Why?
| | Genetic Diseases, Inborn | 1 | 2019 | 19 | 0.180 |
Why?
| | Cohort Studies | 4 | 2019 | 262 | 0.180 |
Why?
| | Vitamin D | 1 | 2019 | 22 | 0.170 |
Why?
| | Steroid 16-alpha-Hydroxylase | 2 | 1998 | 8 | 0.170 |
Why?
| | Preoperative Care | 1 | 2019 | 27 | 0.170 |
Why?
| | Bone Density | 1 | 2019 | 44 | 0.170 |
Why?
| | Laminectomy | 2 | 2015 | 5 | 0.170 |
Why?
| | Internal Mammary-Coronary Artery Anastomosis | 1 | 1998 | 1 | 0.170 |
Why?
| | Electronic Health Records | 1 | 2019 | 61 | 0.170 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 37 | 0.170 |
Why?
| | Ion Channels | 1 | 2018 | 4 | 0.170 |
Why?
| | Hydrops Fetalis | 1 | 2018 | 5 | 0.170 |
Why?
| | Intraoperative Care | 2 | 1998 | 8 | 0.170 |
Why?
| | Exome | 1 | 2018 | 35 | 0.170 |
Why?
| | Gene Expression Regulation | 2 | 1998 | 100 | 0.160 |
Why?
| | Acute Disease | 5 | 2017 | 76 | 0.160 |
Why?
| | Recurrence | 5 | 2005 | 119 | 0.160 |
Why?
| | Carbon Radioisotopes | 2 | 2017 | 4 | 0.160 |
Why?
| | Codon | 1 | 1998 | 4 | 0.160 |
Why?
| | Chest Pain | 1 | 1998 | 4 | 0.160 |
Why?
| | Fat Necrosis | 1 | 2017 | 1 | 0.160 |
Why?
| | Kallikreins | 1 | 2017 | 1 | 0.160 |
Why?
| | Abdomen | 1 | 2017 | 14 | 0.160 |
Why?
| | Cardiovascular Agents | 1 | 2017 | 1 | 0.160 |
Why?
| | Patient Admission | 1 | 1998 | 10 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C9 | 4 | 2009 | 29 | 0.160 |
Why?
| | Molecular Sequence Data | 7 | 1998 | 72 | 0.160 |
Why?
| | Photogrammetry | 1 | 2017 | 1 | 0.160 |
Why?
| | Face | 1 | 2017 | 4 | 0.160 |
Why?
| | Arthritis, Experimental | 1 | 1997 | 1 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 1997 | 3 | 0.160 |
Why?
| | Tibial Fractures | 2 | 1994 | 2 | 0.150 |
Why?
| | Hysterosalpingography | 1 | 2017 | 1 | 0.150 |
Why?
| | Endosonography | 1 | 2017 | 2 | 0.150 |
Why?
| | Mutation | 2 | 1998 | 197 | 0.150 |
Why?
| | Biopsy | 3 | 2018 | 60 | 0.150 |
Why?
| | Radiosurgery | 1 | 2017 | 1 | 0.150 |
Why?
| | Equipment and Supplies | 1 | 2017 | 1 | 0.150 |
Why?
| | Choline | 1 | 2017 | 3 | 0.150 |
Why?
| | Fluoroscopy | 1 | 1997 | 20 | 0.150 |
Why?
| | Punctures | 1 | 2017 | 1 | 0.150 |
Why?
| | Orthopedic Procedures | 2 | 2015 | 18 | 0.150 |
Why?
| | Blood Vessel Prosthesis | 1 | 2017 | 3 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 2 | 0.150 |
Why?
| | Point-of-Care Systems | 1 | 1997 | 11 | 0.150 |
Why?
| | Phlebography | 1 | 2017 | 7 | 0.150 |
Why?
| | Intrauterine Devices | 1 | 2017 | 4 | 0.150 |
Why?
| | Humeral Head | 1 | 2017 | 1 | 0.150 |
Why?
| | Osteoarthritis | 1 | 2017 | 3 | 0.150 |
Why?
| | Arabs | 1 | 1997 | 2 | 0.150 |
Why?
| | DNA | 3 | 1995 | 42 | 0.150 |
Why?
| | Genetic Variation | 1 | 2018 | 163 | 0.150 |
Why?
| | Ultrasonography, Prenatal | 3 | 2023 | 11 | 0.150 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 5 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 14 | 0.150 |
Why?
| | Salvage Therapy | 1 | 2017 | 9 | 0.150 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2016 | 1 | 0.150 |
Why?
| | Lymph Nodes | 1 | 2016 | 3 | 0.150 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 38 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 55 | 0.140 |
Why?
| | Cadaver | 3 | 2017 | 21 | 0.140 |
Why?
| | Isoenzymes | 4 | 1998 | 23 | 0.140 |
Why?
| | Postmenopause | 2 | 2013 | 6 | 0.140 |
Why?
| | Liver | 3 | 1998 | 123 | 0.140 |
Why?
| | Thoracic Vertebrae | 1 | 1996 | 5 | 0.140 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 6 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 12 | 0.140 |
Why?
| | Point Mutation | 1 | 1995 | 6 | 0.140 |
Why?
| | Thoracoscopy | 1 | 1996 | 28 | 0.140 |
Why?
| | Streptokinase | 1 | 1995 | 1 | 0.130 |
Why?
| | Fiducial Markers | 1 | 2015 | 2 | 0.130 |
Why?
| | Reperfusion Injury | 1 | 1995 | 2 | 0.130 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2015 | 2 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2015 | 32 | 0.130 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 312 | 0.130 |
Why?
| | Hemorrhage | 3 | 2009 | 21 | 0.130 |
Why?
| | Phosphoproteins | 1 | 1995 | 12 | 0.130 |
Why?
| | Tibia | 2 | 1994 | 3 | 0.130 |
Why?
| | Mutagenesis, Site-Directed | 4 | 1999 | 23 | 0.130 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2015 | 6 | 0.130 |
Why?
| | Aspirin | 1 | 2015 | 6 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 1995 | 37 | 0.130 |
Why?
| | Transcription, Genetic | 1 | 1995 | 45 | 0.130 |
Why?
| | Craniotomy | 4 | 2004 | 4 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 4 | 2017 | 32 | 0.130 |
Why?
| | Promoter Regions, Genetic | 1 | 1995 | 48 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 218 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 1 | 2015 | 29 | 0.130 |
Why?
| | Drainage | 1 | 2015 | 35 | 0.130 |
Why?
| | Bone and Bones | 1 | 1995 | 17 | 0.130 |
Why?
| | Graft Survival | 1 | 1995 | 32 | 0.130 |
Why?
| | Renal Artery Obstruction | 2 | 2006 | 3 | 0.130 |
Why?
| | Base Sequence | 6 | 1998 | 83 | 0.130 |
Why?
| | Databases, Bibliographic | 1 | 2014 | 1 | 0.130 |
Why?
| | Journal Impact Factor | 1 | 2014 | 2 | 0.130 |
Why?
| | Myocardial Reperfusion | 1 | 1994 | 1 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 2014 | 5 | 0.130 |
Why?
| | Arrhythmias, Cardiac | 1 | 1994 | 3 | 0.130 |
Why?
| | Linear Models | 1 | 2014 | 55 | 0.120 |
Why?
| | Heart Arrest, Induced | 1 | 1994 | 1 | 0.120 |
Why?
| | Hypothermia, Induced | 1 | 1994 | 2 | 0.120 |
Why?
| | Biocompatible Materials | 3 | 2004 | 5 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 43 | 0.120 |
Why?
| | Patient Readmission | 1 | 2015 | 67 | 0.120 |
Why?
| | Lymphocele | 1 | 1994 | 1 | 0.120 |
Why?
| | Inguinal Canal | 1 | 1994 | 4 | 0.120 |
Why?
| | Muscles | 1 | 1994 | 3 | 0.120 |
Why?
| | Sodium Chloride | 2 | 2004 | 5 | 0.120 |
Why?
| | Device Approval | 3 | 2011 | 3 | 0.120 |
Why?
| | United States Food and Drug Administration | 3 | 2011 | 7 | 0.120 |
Why?
| | Prognosis | 5 | 2017 | 213 | 0.120 |
Why?
| | Vaginal Diseases | 1 | 2013 | 1 | 0.120 |
Why?
| | Mammaplasty | 1 | 1993 | 5 | 0.120 |
Why?
| | Serum Albumin, Bovine | 1 | 1993 | 1 | 0.120 |
Why?
| | Peripheral Arterial Disease | 1 | 2013 | 3 | 0.120 |
Why?
| | Ankylosis | 1 | 1993 | 2 | 0.110 |
Why?
| | Temporomandibular Joint Disorders | 1 | 1993 | 2 | 0.110 |
Why?
| | Hydrogen Peroxide | 1 | 1993 | 2 | 0.110 |
Why?
| | In Vitro Techniques | 2 | 2011 | 23 | 0.110 |
Why?
| | Macrophages | 1 | 1993 | 5 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 55 | 0.110 |
Why?
| | Biomechanical Phenomena | 2 | 2011 | 8 | 0.110 |
Why?
| | Laparoscopy | 1 | 1996 | 217 | 0.110 |
Why?
| | Europe | 4 | 2013 | 37 | 0.110 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 99 | 0.110 |
Why?
| | Pregnancy Outcome | 2 | 2023 | 5 | 0.110 |
Why?
| | Intermittent Claudication | 1 | 2012 | 1 | 0.110 |
Why?
| | Serine | 1 | 1992 | 3 | 0.110 |
Why?
| | Fracture Healing | 3 | 1999 | 4 | 0.100 |
Why?
| | Surgical Equipment | 2 | 2005 | 3 | 0.100 |
Why?
| | Echocardiography, Transesophageal | 2 | 2020 | 10 | 0.100 |
Why?
| | Reference Values | 4 | 1997 | 43 | 0.100 |
Why?
| | Polymers | 2 | 2004 | 5 | 0.100 |
Why?
| | Confidence Intervals | 2 | 2004 | 14 | 0.100 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2011 | 1 | 0.100 |
Why?
| | Silicone Elastomers | 1 | 1991 | 1 | 0.100 |
Why?
| | Microsomes, Liver | 3 | 1996 | 45 | 0.100 |
Why?
| | Breast | 1 | 1991 | 5 | 0.100 |
Why?
| | Transplantation, Homologous | 1 | 2011 | 21 | 0.100 |
Why?
| | Vascular Patency | 3 | 2013 | 3 | 0.100 |
Why?
| | Age Factors | 3 | 2019 | 204 | 0.100 |
Why?
| | Joint Instability | 1 | 2011 | 3 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 37 | 0.100 |
Why?
| | Young Adult | 3 | 2019 | 616 | 0.100 |
Why?
| | Endometrium | 1 | 2010 | 1 | 0.090 |
Why?
| | Estrogens | 1 | 2010 | 3 | 0.090 |
Why?
| | Estradiol | 1 | 2010 | 9 | 0.090 |
Why?
| | Zygapophyseal Joint | 1 | 2010 | 1 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2020 | 144 | 0.090 |
Why?
| | Oxidation-Reduction | 3 | 1995 | 12 | 0.090 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 1 | 0.090 |
Why?
| | Pancreatitis | 1 | 1989 | 9 | 0.090 |
Why?
| | Endoscopy | 1 | 2010 | 16 | 0.090 |
Why?
| | Insulin Resistance | 1 | 1989 | 12 | 0.090 |
Why?
| | Amino Acid Sequence | 4 | 1998 | 31 | 0.090 |
Why?
| | RNA, Messenger | 1 | 1990 | 111 | 0.090 |
Why?
| | Joint Prosthesis | 1 | 2009 | 2 | 0.090 |
Why?
| | Prevalence | 2 | 2022 | 146 | 0.090 |
Why?
| | Risk Assessment | 3 | 2020 | 131 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 262 | 0.090 |
Why?
| | Multivariate Analysis | 2 | 2017 | 72 | 0.090 |
Why?
| | Ultrasonography | 3 | 2010 | 45 | 0.090 |
Why?
| | Pedigree | 2 | 2022 | 56 | 0.090 |
Why?
| | Morbidity | 2 | 2022 | 13 | 0.090 |
Why?
| | Dioxins | 1 | 1988 | 1 | 0.080 |
Why?
| | Liver Neoplasms, Experimental | 1 | 1988 | 1 | 0.080 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 1988 | 3 | 0.080 |
Why?
| | DNA Mutational Analysis | 1 | 2008 | 37 | 0.080 |
Why?
| | Comorbidity | 1 | 2008 | 56 | 0.080 |
Why?
| | Genotype | 5 | 2009 | 401 | 0.080 |
Why?
| | Pain, Postoperative | 2 | 2022 | 41 | 0.080 |
Why?
| | Coronary Artery Bypass | 2 | 2000 | 2 | 0.080 |
Why?
| | Articulation Disorders | 1 | 2008 | 1 | 0.080 |
Why?
| | Speech Production Measurement | 1 | 2008 | 1 | 0.080 |
Why?
| | Speech | 1 | 2008 | 2 | 0.080 |
Why?
| | Voice Disorders | 1 | 2008 | 2 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2009 | 92 | 0.080 |
Why?
| | Feasibility Studies | 3 | 1998 | 56 | 0.080 |
Why?
| | Movement | 1 | 2008 | 7 | 0.080 |
Why?
| | Obesity | 1 | 2009 | 123 | 0.080 |
Why?
| | Ultrasonography, Doppler, Duplex | 3 | 2013 | 3 | 0.080 |
Why?
| | Image Processing, Computer-Assisted | 3 | 1997 | 17 | 0.080 |
Why?
| | Encephalocele | 3 | 2000 | 4 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2017 | 77 | 0.080 |
Why?
| | Water | 2 | 2003 | 6 | 0.080 |
Why?
| | Narcotics | 1 | 2007 | 6 | 0.080 |
Why?
| | Length of Stay | 3 | 2009 | 232 | 0.070 |
Why?
| | Recombinant Proteins | 4 | 1996 | 51 | 0.070 |
Why?
| | Plasmids | 2 | 1999 | 7 | 0.070 |
Why?
| | Coronary Circulation | 2 | 1998 | 3 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2006 | 3 | 0.070 |
Why?
| | Rats, Inbred Lew | 3 | 1997 | 4 | 0.070 |
Why?
| | Angioscopy | 2 | 1995 | 2 | 0.070 |
Why?
| | Canada | 2 | 2017 | 33 | 0.070 |
Why?
| | Rats, Inbred Strains | 3 | 1990 | 4 | 0.070 |
Why?
| | Kinetics | 3 | 1993 | 34 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2017 | 47 | 0.070 |
Why?
| | Polyglycolic Acid | 1 | 2004 | 1 | 0.060 |
Why?
| | Lactic Acid | 1 | 2004 | 4 | 0.060 |
Why?
| | Skin | 1 | 2004 | 16 | 0.060 |
Why?
| | Sumatriptan | 1 | 2004 | 1 | 0.060 |
Why?
| | Tryptamines | 1 | 2004 | 2 | 0.060 |
Why?
| | Craniofacial Abnormalities | 1 | 2004 | 11 | 0.060 |
Why?
| | Hypertension | 1 | 1985 | 61 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2004 | 39 | 0.060 |
Why?
| | Zygoma | 2 | 1995 | 2 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 27 | 0.060 |
Why?
| | Reoperation | 3 | 2005 | 60 | 0.060 |
Why?
| | Behavior, Animal | 1 | 2003 | 1 | 0.060 |
Why?
| | Osteotomy | 2 | 1994 | 3 | 0.060 |
Why?
| | Cloning, Molecular | 3 | 1998 | 10 | 0.060 |
Why?
| | Intensive Care Units | 1 | 2023 | 18 | 0.060 |
Why?
| | North America | 1 | 2023 | 42 | 0.060 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2003 | 6 | 0.060 |
Why?
| | Incidence | 3 | 2017 | 128 | 0.060 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2003 | 1 | 0.060 |
Why?
| | Parturition | 1 | 2023 | 2 | 0.060 |
Why?
| | Fetal Development | 1 | 2023 | 5 | 0.060 |
Why?
| | South Africa | 1 | 2023 | 7 | 0.060 |
Why?
| | Free Radicals | 2 | 1993 | 2 | 0.060 |
Why?
| | Coronary Stenosis | 1 | 2003 | 1 | 0.060 |
Why?
| | Toes | 1 | 2002 | 1 | 0.060 |
Why?
| | Dancing | 1 | 2002 | 2 | 0.060 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 35 | 0.050 |
Why?
| | Constriction, Pathologic | 2 | 2013 | 19 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 1999 | 10 | 0.050 |
Why?
| | Blood Flow Velocity | 2 | 2020 | 8 | 0.050 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 27 | 0.050 |
Why?
| | Fentanyl | 1 | 2022 | 2 | 0.050 |
Why?
| | Atrial Function, Right | 2 | 1992 | 2 | 0.050 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 2 | 1999 | 7 | 0.050 |
Why?
| | Acoustic Impedance Tests | 1 | 2002 | 1 | 0.050 |
Why?
| | Tape Recording | 1 | 2002 | 1 | 0.050 |
Why?
| | Matched-Pair Analysis | 1 | 2002 | 2 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 8 | 0.050 |
Why?
| | Introns | 2 | 1999 | 9 | 0.050 |
Why?
| | Child Language | 1 | 2002 | 5 | 0.050 |
Why?
| | Aftercare | 1 | 2022 | 5 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2002 | 19 | 0.050 |
Why?
| | Genome | 1 | 2022 | 33 | 0.050 |
Why?
| | Cholinesterase Inhibitors | 1 | 2001 | 1 | 0.050 |
Why?
| | Models, Molecular | 1 | 2001 | 15 | 0.050 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 43 | 0.050 |
Why?
| | Penetrance | 1 | 2021 | 1 | 0.050 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2021 | 4 | 0.050 |
Why?
| | Antibodies, Antinuclear | 1 | 2021 | 4 | 0.050 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2021 | 4 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 7 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2021 | 9 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2021 | 15 | 0.050 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2001 | 47 | 0.050 |
Why?
| | Pregnancy, Twin | 1 | 2021 | 1 | 0.050 |
Why?
| | Twins, Monozygotic | 1 | 2021 | 7 | 0.050 |
Why?
| | Chronic Disease | 2 | 1993 | 105 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2021 | 8 | 0.050 |
Why?
| | Heart Atria | 2 | 1991 | 4 | 0.050 |
Why?
| | Sheep | 3 | 1999 | 4 | 0.050 |
Why?
| | Genome, Human | 1 | 2001 | 83 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 97 | 0.050 |
Why?
| | Mothers | 1 | 2021 | 32 | 0.050 |
Why?
| | Cystic Fibrosis | 2 | 2019 | 20 | 0.050 |
Why?
| | Silicones | 2 | 1991 | 2 | 0.050 |
Why?
| | Genetic Testing | 1 | 2021 | 76 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2020 | 6 | 0.050 |
Why?
| | Heterozygote | 2 | 1997 | 25 | 0.050 |
Why?
| | Homozygote | 2 | 1997 | 20 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2019 | 9 | 0.050 |
Why?
| | France | 1 | 1999 | 1 | 0.040 |
Why?
| | Omeprazole | 2 | 1996 | 14 | 0.040 |
Why?
| | Anti-Ulcer Agents | 2 | 1996 | 10 | 0.040 |
Why?
| | Pseudarthrosis | 1 | 2019 | 1 | 0.040 |
Why?
| | Exons | 1 | 1999 | 34 | 0.040 |
Why?
| | Osseointegration | 1 | 1999 | 1 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 69 | 0.040 |
Why?
| | Educational Status | 1 | 2019 | 20 | 0.040 |
Why?
| | Insurance, Health | 1 | 2019 | 17 | 0.040 |
Why?
| | Escherichia coli | 1 | 1999 | 28 | 0.040 |
Why?
| | Pressure | 2 | 2002 | 13 | 0.040 |
Why?
| | Saphenous Vein | 2 | 1995 | 2 | 0.040 |
Why?
| | Atherectomy, Coronary | 2 | 1995 | 2 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 81 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2019 | 20 | 0.040 |
Why?
| | Malates | 1 | 1978 | 1 | 0.040 |
Why?
| | Oxaloacetates | 1 | 1978 | 1 | 0.040 |
Why?
| | Pyruvates | 1 | 1978 | 1 | 0.040 |
Why?
| | Lung | 1 | 1999 | 66 | 0.040 |
Why?
| | Autopsy | 1 | 2018 | 1 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 96 | 0.040 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1998 | 41 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 2 | 2009 | 4 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2018 | 54 | 0.040 |
Why?
| | Facial Bones | 2 | 2000 | 2 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 1998 | 6 | 0.040 |
Why?
| | SEER Program | 1 | 2017 | 7 | 0.040 |
Why?
| | Abdominal Neoplasms | 1 | 2017 | 6 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2017 | 20 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2017 | 32 | 0.040 |
Why?
| | Regression Analysis | 1 | 1998 | 52 | 0.040 |
Why?
| | Foot | 1 | 1997 | 1 | 0.040 |
Why?
| | Freund's Adjuvant | 1 | 1997 | 1 | 0.040 |
Why?
| | Breast Implants | 1 | 1997 | 2 | 0.040 |
Why?
| | Mycobacterium | 1 | 1997 | 3 | 0.040 |
Why?
| | Antigens | 1 | 1997 | 4 | 0.040 |
Why?
| | Autoimmune Diseases | 1 | 1997 | 12 | 0.040 |
Why?
| | Connective Tissue Diseases | 1 | 1997 | 5 | 0.040 |
Why?
| | Postoperative Period | 1 | 1997 | 18 | 0.040 |
Why?
| | Fallopian Tubes | 1 | 2017 | 1 | 0.040 |
Why?
| | Hysteroscopy | 1 | 2017 | 1 | 0.040 |
Why?
| | Spain | 1 | 2017 | 3 | 0.040 |
Why?
| | Netherlands | 1 | 2017 | 5 | 0.040 |
Why?
| | Uterus | 1 | 2017 | 9 | 0.040 |
Why?
| | Africa | 1 | 2017 | 4 | 0.040 |
Why?
| | Anatomic Landmarks | 1 | 2017 | 1 | 0.040 |
Why?
| | Biodegradation, Environmental | 1 | 1997 | 1 | 0.040 |
Why?
| | Anti-HIV Agents | 1 | 2017 | 10 | 0.040 |
Why?
| | Saudi Arabia | 1 | 1997 | 1 | 0.040 |
Why?
| | Taiwan | 1 | 1997 | 1 | 0.040 |
Why?
| | Philippines | 1 | 1997 | 2 | 0.040 |
Why?
| | Substrate Specificity | 2 | 1996 | 18 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 37 | 0.040 |
Why?
| | Hydroxylation | 2 | 1996 | 14 | 0.040 |
Why?
| | Androgen Antagonists | 1 | 2017 | 1 | 0.040 |
Why?
| | Radiotherapy, Conformal | 1 | 2017 | 1 | 0.040 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 2 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2017 | 3 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 9 | 0.040 |
Why?
| | Risk | 1 | 2017 | 39 | 0.040 |
Why?
| | Stereoisomerism | 2 | 1995 | 11 | 0.040 |
Why?
| | Thrombolytic Therapy | 1 | 1996 | 6 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 1998 | 124 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2017 | 191 | 0.040 |
Why?
| | Spinal Cord Compression | 1 | 1996 | 1 | 0.030 |
Why?
| | Bone Wires | 1 | 1995 | 1 | 0.030 |
Why?
| | Plasminogen Activators | 1 | 1995 | 1 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 1 | 0.030 |
Why?
| | Nanostructures | 1 | 2015 | 1 | 0.030 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 1995 | 2 | 0.030 |
Why?
| | Spinal Injuries | 1 | 1995 | 4 | 0.030 |
Why?
| | Spinal Fractures | 1 | 1995 | 4 | 0.030 |
Why?
| | Analysis of Variance | 2 | 1995 | 25 | 0.030 |
Why?
| | Liposomes | 1 | 2015 | 3 | 0.030 |
Why?
| | Antibodies | 1 | 2015 | 16 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 14 | 0.030 |
Why?
| | Denmark | 1 | 1995 | 2 | 0.030 |
Why?
| | Japan | 1 | 1995 | 3 | 0.030 |
Why?
| | Video Recording | 1 | 1996 | 14 | 0.030 |
Why?
| | Genes, Recessive | 1 | 1995 | 7 | 0.030 |
Why?
| | Fractures, Closed | 1 | 1995 | 1 | 0.030 |
Why?
| | External Fixators | 1 | 1995 | 1 | 0.030 |
Why?
| | Fracture Fixation | 1 | 1995 | 2 | 0.030 |
Why?
| | Pelvic Bones | 1 | 1995 | 9 | 0.030 |
Why?
| | Gold | 1 | 2015 | 1 | 0.030 |
Why?
| | Perineum | 1 | 2015 | 3 | 0.030 |
Why?
| | Online Systems | 1 | 1995 | 1 | 0.030 |
Why?
| | Atrial Function, Left | 1 | 1995 | 1 | 0.030 |
Why?
| | Family | 1 | 1995 | 27 | 0.030 |
Why?
| | Haplorhini | 1 | 1995 | 3 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 1995 | 2 | 0.030 |
Why?
| | Hepatocyte Nuclear Factor 4 | 1 | 1995 | 4 | 0.030 |
Why?
| | Transfection | 1 | 1995 | 21 | 0.030 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1995 | 5 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1995 | 9 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 1995 | 25 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2015 | 13 | 0.030 |
Why?
| | Gene Deletion | 1 | 1995 | 13 | 0.030 |
Why?
| | Binding Sites | 1 | 1995 | 27 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 2015 | 2 | 0.030 |
Why?
| | Liver Neoplasms | 1 | 1995 | 16 | 0.030 |
Why?
| | Lumbosacral Region | 1 | 2015 | 2 | 0.030 |
Why?
| | Smallpox | 1 | 1975 | 1 | 0.030 |
Why?
| | Transcription Factors | 1 | 1995 | 48 | 0.030 |
Why?
| | Vaccinia | 1 | 1975 | 2 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 1975 | 2 | 0.030 |
Why?
| | Rabbits | 1 | 1995 | 6 | 0.030 |
Why?
| | Patient Compliance | 1 | 2015 | 56 | 0.030 |
Why?
| | Thrombosis | 1 | 2015 | 16 | 0.030 |
Why?
| | Myocardium | 1 | 1994 | 9 | 0.030 |
Why?
| | Ligation | 1 | 2014 | 4 | 0.030 |
Why?
| | Vaccination | 1 | 1975 | 70 | 0.030 |
Why?
| | Electric Injuries | 1 | 1994 | 1 | 0.030 |
Why?
| | Hindlimb | 1 | 1994 | 2 | 0.030 |
Why?
| | Cineradiography | 1 | 1994 | 1 | 0.030 |
Why?
| | Ventricular Pressure | 1 | 1994 | 4 | 0.030 |
Why?
| | Radiography, Interventional | 1 | 1994 | 2 | 0.030 |
Why?
| | Endothelium, Vascular | 1 | 1994 | 6 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 1994 | 8 | 0.030 |
Why?
| | Lymph | 1 | 1994 | 1 | 0.030 |
Why?
| | Exudates and Transudates | 1 | 1994 | 2 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1994 | 25 | 0.030 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 1994 | 1 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 1994 | 4 | 0.030 |
Why?
| | Contrast Media | 1 | 1994 | 25 | 0.030 |
Why?
| | Heart Valve Prosthesis | 1 | 1994 | 7 | 0.030 |
Why?
| | Registries | 1 | 2014 | 86 | 0.030 |
Why?
| | Catheterization | 1 | 1994 | 28 | 0.030 |
Why?
| | Graft Rejection | 1 | 1994 | 32 | 0.030 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2013 | 1 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 2013 | 1 | 0.030 |
Why?
| | Fracture Fixation, Internal | 1 | 1993 | 1 | 0.030 |
Why?
| | Women's Health | 1 | 2013 | 2 | 0.030 |
Why?
| | Mandibulofacial Dysostosis | 1 | 1993 | 3 | 0.030 |
Why?
| | Surgical Mesh | 1 | 1993 | 9 | 0.030 |
Why?
| | Oligopeptides | 1 | 1993 | 1 | 0.030 |
Why?
| | Cross-Linking Reagents | 1 | 1993 | 2 | 0.030 |
Why?
| | Dipeptides | 1 | 1993 | 2 | 0.030 |
Why?
| | Ventricular Function | 1 | 1993 | 6 | 0.030 |
Why?
| | Skull Fractures | 1 | 1993 | 1 | 0.030 |
Why?
| | Skull Neoplasms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2013 | 2 | 0.030 |
Why?
| | Exercise Tolerance | 1 | 2013 | 8 | 0.030 |
Why?
| | Spectrum Analysis | 1 | 1993 | 1 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 1993 | 9 | 0.030 |
Why?
| | Exercise Test | 1 | 2013 | 18 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1993 | 7 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1993 | 21 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 1993 | 17 | 0.030 |
Why?
| | Surgery, Plastic | 1 | 1993 | 1 | 0.030 |
Why?
| | Cells, Cultured | 1 | 1993 | 81 | 0.030 |
Why?
| | Creatine Kinase | 1 | 1992 | 1 | 0.030 |
Why?
| | Quality of Life | 1 | 2013 | 135 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 1992 | 4 | 0.030 |
Why?
| | Dopamine | 1 | 1992 | 6 | 0.030 |
Why?
| | Cysteine | 1 | 1992 | 1 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1992 | 1 | 0.030 |
Why?
| | Enzyme Stability | 1 | 1992 | 4 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1992 | 2 | 0.030 |
Why?
| | Restriction Mapping | 1 | 1992 | 6 | 0.030 |
Why?
| | Blotting, Western | 1 | 1992 | 17 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 18 | 0.020 |
Why?
| | New York City | 1 | 2011 | 2 | 0.020 |
Why?
| | Ilium | 1 | 2011 | 2 | 0.020 |
Why?
| | Cardiac Output | 1 | 1990 | 2 | 0.020 |
Why?
| | Cardiac Pacing, Artificial | 1 | 1990 | 2 | 0.020 |
Why?
| | Diuretics | 2 | 2004 | 6 | 0.020 |
Why?
| | Polyurethanes | 1 | 1990 | 1 | 0.020 |
Why?
| | Connective Tissue | 1 | 1990 | 3 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 2010 | 3 | 0.020 |
Why?
| | Wound Healing | 1 | 1990 | 8 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2010 | 1 | 0.020 |
Why?
| | Angiography | 1 | 2010 | 9 | 0.020 |
Why?
| | Blood Pressure | 1 | 1990 | 58 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 2 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 4 | 0.020 |
Why?
| | Oligonucleotides | 1 | 1990 | 5 | 0.020 |
Why?
| | Oleic Acids | 1 | 1989 | 1 | 0.020 |
Why?
| | Oleic Acid | 1 | 1989 | 1 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 4 | 0.020 |
Why?
| | Glucose | 1 | 1989 | 23 | 0.020 |
Why?
| | Blood Glucose | 1 | 1989 | 54 | 0.020 |
Why?
| | Time | 1 | 2009 | 7 | 0.020 |
Why?
| | International Normalized Ratio | 1 | 2009 | 5 | 0.020 |
Why?
| | Carcinogens | 1 | 1988 | 2 | 0.020 |
Why?
| | Immunologic Techniques | 1 | 1988 | 2 | 0.020 |
Why?
| | NADPH-Ferrihemoprotein Reductase | 1 | 1988 | 3 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 6 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 1988 | 36 | 0.020 |
Why?
| | Malaria | 1 | 1988 | 4 | 0.020 |
Why?
| | Body Mass Index | 1 | 2009 | 154 | 0.020 |
Why?
| | Anesthesia Department, Hospital | 1 | 2007 | 1 | 0.020 |
Why?
| | Fees and Charges | 1 | 2007 | 1 | 0.020 |
Why?
| | Medicare | 1 | 2007 | 3 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2007 | 5 | 0.020 |
Why?
| | Operating Rooms | 1 | 2007 | 6 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2009 | 171 | 0.020 |
Why?
| | Rats, Inbred SHR | 1 | 1985 | 1 | 0.020 |
Why?
| | Rats, Inbred WKY | 1 | 1985 | 1 | 0.020 |
Why?
| | Salivary Glands | 1 | 1985 | 1 | 0.020 |
Why?
| | Food Deprivation | 1 | 1985 | 2 | 0.020 |
Why?
| | Eating | 1 | 1985 | 31 | 0.020 |
Why?
| | Lanthanum | 1 | 2004 | 1 | 0.020 |
Why?
| | Skin Absorption | 1 | 2004 | 1 | 0.020 |
Why?
| | Adsorption | 1 | 2004 | 2 | 0.020 |
Why?
| | Amiloride | 1 | 2004 | 2 | 0.020 |
Why?
| | Tight Junctions | 1 | 2004 | 5 | 0.020 |
Why?
| | Potassium | 1 | 2004 | 9 | 0.020 |
Why?
| | Diet | 1 | 1985 | 53 | 0.020 |
Why?
| | Signal Transduction | 1 | 2004 | 126 | 0.010 |
Why?
| | Hypertension, Renovascular | 1 | 2003 | 4 | 0.010 |
Why?
| | Hallux | 1 | 2002 | 1 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2002 | 12 | 0.010 |
Why?
| | Orbit | 1 | 2000 | 1 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 1 | 0.010 |
Why?
| | Weight-Bearing | 1 | 1999 | 1 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 1999 | 9 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1999 | 57 | 0.010 |
Why?
| | Chemistry | 1 | 1978 | 1 | 0.010 |
Why?
| | Pyruvate Kinase | 1 | 1978 | 1 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1978 | 1 | 0.010 |
Why?
| | Chemical Phenomena | 1 | 1978 | 1 | 0.010 |
Why?
| | Deuterium | 1 | 1978 | 2 | 0.010 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 1978 | 11 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 6 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 22 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1996 | 42 | 0.010 |
Why?
| | Treatment Failure | 1 | 1996 | 17 | 0.010 |
Why?
| | Lansoprazole | 1 | 1996 | 2 | 0.010 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 1996 | 7 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 1995 | 1 | 0.010 |
Why?
| | China | 1 | 1995 | 10 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1995 | 47 | 0.010 |
Why?
| | Mitral Valve | 1 | 1995 | 5 | 0.010 |
Why?
| | Diastole | 1 | 1995 | 12 | 0.010 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 1975 | 1 | 0.010 |
Why?
| | Eye Diseases | 1 | 1975 | 1 | 0.010 |
Why?
| | Eczema | 1 | 1975 | 2 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1975 | 6 | 0.010 |
Why?
| | Erythema | 1 | 1975 | 6 | 0.010 |
Why?
| | Immunotherapy | 1 | 1975 | 15 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 146 | 0.010 |
Why?
| | Tricuspid Valve | 1 | 1994 | 1 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1994 | 3 | 0.010 |
Why?
| | Survival Analysis | 1 | 1994 | 47 | 0.010 |
Why?
| | Collagen | 1 | 1993 | 4 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1993 | 4 | 0.010 |
Why?
| | Clinical Enzyme Tests | 1 | 1992 | 1 | 0.010 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1992 | 1 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1990 | 5 | 0.010 |
Why?
| | Plasmodium vivax | 1 | 1988 | 1 | 0.010 |
Why?
| | Plasmodium falciparum | 1 | 1988 | 2 | 0.010 |
Why?
| | Travel | 1 | 1988 | 7 | 0.010 |
Why?
| | Antimalarials | 1 | 1988 | 7 | 0.010 |
Why?
| | Fever | 1 | 1988 | 27 | 0.010 |
Why?
| | Gastrointestinal Diseases | 1 | 1988 | 46 | 0.000 |
Why?
| | Parotid Gland | 1 | 1965 | 1 | 0.000 |
Why?
| | Salivation | 1 | 1965 | 3 | 0.000 |
Why?
| | Iothalamate Meglumine | 1 | 1984 | 1 | 0.000 |
Why?
| | Iothalamic Acid | 1 | 1984 | 1 | 0.000 |
Why?
| | Drug Combinations | 1 | 1984 | 20 | 0.000 |
Why?
| | Image Enhancement | 1 | 1984 | 14 | 0.000 |
Why?
| | Heart | 1 | 1984 | 16 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Physical Neighbors People whose addresses are nearby this person. _
|